NASDAQ:FOLD - Amicus Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $20.42
Forecasted Upside: 105.61 %
Number of Analysts: 13
Breakdown:
0 Sell Ratings
7 Hold Ratings
6 Buy Ratings
0 Strong Buy Ratings

^$9.93 As of 06/18/2021 01:00 AM ET

▼ -0.27 (-2.65%)

1 month | 3 months | 12 months

Get New Amicus Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for FOLD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FOLD

^$20.42

▲ +105.61% Upside Potential

This price target is based on 13 analysts offering 12 month price targets for Amicus Therapeutics in the last 3 months. The average price target is $20.42, with a high forecast of $31.00 and a low forecast of $13.00. The average price target represents a 105.61% upside from the last price of $9.93.

Hold

The current consensus among 13 investment analysts is to hold stock in Amicus Therapeutics. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/28/2019

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/27/2020

0 strong buy ratings
5 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/25/2020

0 strong buy ratings
6 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

9/23/2020

0 strong buy ratings
6 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

12/22/2020

0 strong buy ratings
6 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

3/22/2021

0 strong buy ratings
7 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

5/21/2021

0 strong buy ratings
6 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

6/20/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/10/2021	SVB Leerink	Reiterated Rating	Hold		High
5/27/2021	Needham & Company LLC	Initiated Coverage	Hold		Low
5/20/2021	UBS Group	Initiated Coverage	Buy	$16.00	High
4/19/2021	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight		N/A
4/13/2021	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$17.00 ➝ $17.00	High
3/22/2021	SVB Leerink	Lower Price Target	Market Perform	$15.00 ➝ $13.00	N/A
3/8/2021	Stifel Nicolaus	Initiated Coverage	Hold	$13.00	N/A
3/3/2021	Robert W. Baird	Reiterated Rating	Buy		High
3/1/2021	Stifel Nicolaus	Initiated Coverage	Hold	$13.00 ➝ $13.00	High
2/12/2021	Citigroup	Lower Price Target		$27.00 ➝ $16.00	Low
2/12/2021	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$30.00 ➝ $15.00	Low
2/12/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$19.00	Low
2/12/2021	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$30.00 ➝ $17.00	Low
12/28/2020	Cantor Fitzgerald	Initiated Coverage	Overweight	$30.00 ➝ $30.00	N/A
12/14/2020	SVB Leerink	Boost Price Target	Positive ➝ Outperform	$24.00 ➝ $30.00	High
12/10/2020	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral	$20.00 ➝ $27.00	Low
12/10/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Downgrade	Buy ➝ Neutral	$20.00 ➝ $27.00	Medium
11/11/2020	Berenberg Bank	Initiated Coverage	Buy ➝ Hold	$21.00	High
11/6/2020	Robert W. Baird	Boost Price Target	Outperform	$20.00 ➝ $25.00	Medium
11/6/2020	SVB Leerink	Boost Price Target	Outperform	$19.00 ➝ $24.00	Medium
10/19/2020	Cowen	Reiterated Rating	Buy	$31.00	Medium
10/9/2020	Cantor Fitzgerald	Reiterated Rating	Overweight		High
8/11/2020	HC Wainwright	Reiterated Rating	Buy	$20.00	High
8/11/2020	Citigroup	Boost Price Target	Buy	$15.00 ➝ $20.00	High
6/16/2020	HC Wainwright	Reiterated Rating	Buy	$20.00	Low
6/16/2020	BTIG Research	Initiated Coverage	Buy	$19.00	Low
6/8/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		High
5/19/2020	SVB Leerink	Reiterated Rating	Outperform ➝ Market Perform	$19.00	High
5/18/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$18.00 ➝ $21.00	High
5/9/2020	Chardan Capital	Reiterated Rating	Hold	$12.50	High
3/5/2020	Chardan Capital	Reiterated Rating	Hold	$12.50	Medium
3/3/2020	HC Wainwright	Reiterated Rating	Buy	$20.00	Low
2/4/2020	Cantor Fitzgerald	Reiterated Rating	Overweight	$19.00 ➝ $20.00	High
1/9/2020	Robert W. Baird	Reiterated Rating	Buy	$20.00	High
1/9/2020	HC Wainwright	Reiterated Rating	Buy	$20.00	High
11/21/2019	HC Wainwright	Reiterated Rating	Buy	$20.00	Medium
11/12/2019	HC Wainwright	Boost Price Target	Buy	$18.00 ➝ $20.00	Low
10/17/2019	Cantor Fitzgerald	Reiterated Rating	Overweight		Medium
10/14/2019	HC Wainwright	Reiterated Rating	Buy	$18.00	Low
10/10/2019	Cowen	Set Price Target	Buy	$31.00	Low
8/1/2019	Cowen	Reiterated Rating	Buy	$31.00	Low
8/1/2019	HC Wainwright	Reiterated Rating	Buy	$18.00	High
7/15/2019	HC Wainwright	Set Price Target	Buy	$18.00	High
7/2/2019	HC Wainwright	Reiterated Rating	Buy	$18.00	Medium
6/17/2019	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$18.00	High
6/5/2019	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $19.00	Low
5/8/2019	Cantor Fitzgerald	Set Price Target	Buy	$20.00	Low
4/22/2019	Robert W. Baird	Set Price Target	Buy	$20.00	Low
4/5/2019	Janney Montgomery Scott	Initiated Coverage	Buy ➝ Buy	$13.91	Medium
2/26/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$20.00	Medium
2/5/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$20.00	Medium
1/29/2019	Cantor Fitzgerald	Initiated Coverage	Overweight	$20.00	Medium
1/16/2019	Citigroup	Upgrade	Neutral ➝ Buy	$12.59	Medium
12/17/2018	Guggenheim	Initiated Coverage	Buy	$18.00	High
10/29/2018	Citigroup	Initiated Coverage	Neutral ➝ Neutral	$12.00	High
10/12/2018	Cowen	Reiterated Rating	Buy	$31.00	Low
10/12/2018	Chardan Capital	Reiterated Rating	Hold	$15.00	High
8/17/2018	Chardan Capital	Downgrade	Buy ➝ Neutral	$18.00 ➝ $15.00	Medium
5/8/2018	Cowen	Reiterated Rating	Buy	$22.00	Medium
2/8/2018	SVB Leerink	Boost Price Target	Outperform ➝ Outperform	$20.00 ➝ $24.00	High
2/7/2018	Robert W. Baird	Set Price Target	Buy	$20.00	High
1/10/2018	Cowen	Reiterated Rating	Buy	$22.00	Medium
10/6/2017	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$17.00	N/A
10/5/2017	Chardan Capital	Reiterated Rating	Buy	$16.50 ➝ $18.50	N/A
10/4/2017	Robert W. Baird	Reiterated Rating	Outperform	$16.00 ➝ $18.00	N/A
10/4/2017	JPMorgan Chase & Co.	Reiterated Rating	Overweight		N/A
10/4/2017	SVB Leerink	Reiterated Rating	Buy	$17.00 ➝ $20.00	Medium
10/4/2017	Bank of America	Boost Price Target	Buy	$15.00 ➝ $20.00	High
9/25/2017	Robert W. Baird	Reiterated Rating	Outperform	$16.00	Low
9/16/2017	SVB Leerink	Reiterated Rating	Outperform	$18.00 ➝ $17.00	Low
9/14/2017	Cowen	Reiterated Rating	Outperform	$16.00 ➝ $18.00	Low
9/13/2017	Chardan Capital	Reiterated Rating	Buy ➝ Buy	$17.50 ➝ $16.50	Low
8/14/2017	Cowen	Reiterated Rating	Buy	$16.00	Low
8/10/2017	Chardan Capital	Boost Price Target	Buy ➝ Buy	$12.50 ➝ $17.50	High
8/9/2017	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$13.00 ➝ $15.00	High
7/12/2017	Robert W. Baird	Boost Price Target	Outperform	$12.00 ➝ $15.00	Medium
7/11/2017	Cowen	Reiterated Rating	Buy	$10.00 ➝ $16.00	Medium
6/30/2017	Robert W. Baird	Reiterated Rating	Outperform	$12.00	Low
6/5/2017	JPMorgan Chase & Co.	Set Price Target	Buy	$13.00	Low
6/1/2017	Chardan Capital	Reiterated Rating	Buy	$12.50	Medium
5/25/2017	Bank of America	Lower Price Target	Buy	$10.00 ➝ $9.00	Medium
5/17/2017	Robert W. Baird	Reiterated Rating	Outperform	$10.00 ➝ $12.00	High
3/30/2017	SVB Leerink	Reiterated Rating	Outperform	$15.00	Medium
1/31/2017	Robert W. Baird	Upgrade	Outperform		N/A
1/24/2017	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$7.00 ➝ $10.00	N/A
12/8/2016	Cowen	Set Price Target	Buy	$12.00	N/A
11/30/2016	SVB Leerink	Reiterated Rating	Outperform	$17.00 ➝ $15.00	N/A
11/30/2016	Cowen	Reiterated Rating	Outperform	$15.00 ➝ $12.00	N/A
11/30/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$12.00 ➝ $11.00	N/A
11/29/2016	Robert W. Baird	Reiterated Rating	Hold	$9.00 ➝ $7.00	N/A
11/29/2016	Chardan Capital	Reiterated Rating	Buy	$15.00 ➝ $16.00	N/A
11/8/2016	SVB Leerink	Reiterated Rating	Buy	$17.00	N/A
11/8/2016	Cowen	Reiterated Rating	Outperform	$15.00	N/A
8/11/2016	Chardan Capital	Set Price Target	Buy	$15.00	N/A

(Data available from 6/20/2016 forward)

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Today's Range

Now: $9.93

$9.68

$10.08

50 Day Range

MA: $9.72

$8.71

$10.72

52 Week Range

Now: $9.93

$8.68

$25.39

Volume

3,519,949 shs

Average Volume

3,436,860 shs

Market Capitalization

$2.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Amicus Therapeutics?

The following equities research analysts have issued reports on Amicus Therapeutics in the last twelve months: Berenberg Bank, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Robert W. Baird, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for FOLD.

What is the current price target for Amicus Therapeutics?

12 Wall Street analysts have set twelve-month price targets for Amicus Therapeutics in the last year. Their average twelve-month price target is $20.42, suggesting a possible upside of 105.6%. Cowen Inc has the highest price target set, predicting FOLD will reach $31.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $13.00 for Amicus Therapeutics in the next year.
View the latest price targets for FOLD.

What is the current consensus analyst rating for Amicus Therapeutics?

Amicus Therapeutics currently has 7 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FOLD, but not buy more shares or sell existing shares.
View the latest ratings for FOLD.

What other companies compete with Amicus Therapeutics?

Other companies that are similar to Amicus Therapeutics include Amgen, Gilead Sciences, Biogen, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Seagen, Exact Sciences, Alnylam Pharmaceuticals, Incyte, BioMarin Pharmaceutical, Novavax, Repligen, Neurocrine Biosciences and United Therapeutics.

How do I contact Amicus Therapeutics' investor relations team?

Amicus Therapeutics' physical mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company's listed phone number is 609-662-2000 and its investor relations email address is [email protected] The official website for Amicus Therapeutics is www.amicusrx.com.